Spondyloepiphyseal Dysplasia, Omani Type

DUBAI, UAE, May 16, 2024 /PRNewswire/ -- XRP Healthcare proudly announces its sponsorship of the upcoming Ehlers-Danlos Society event in Philadelphia this July 17th – 21st. Dedicated to raising awareness and support for individuals living with any of the types of Ehlers-Danlos syndrome (EDS) or hypermobility spectrum disorders (HSD), this event will be a beacon of hope and solidarity for the EDS and HSD community. Continue Reading XRP Healthcare Sponsors The Ehlers-Danlos Society, with Vital Support via its Prescription Savings Card EDS and HSD are a group of heritable connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain, multiple other concerns termed comorbidities, and, in EDS, fragile body tissues that more easily scar, tear or rupture. Managing EDS and HSD often involves a complex treatment regimen, including prescription medications to alleviate pain and other associated conditions. As part of its commitment to improving healthcare accessibility and affordability, XRP Healthcare introduced the XRP Healthcare prescription savings card last year. Now seamlessly integrated into the XRPH App/wallet and available to download on Google Play and iOS store, this innovative solution empowers individuals with EDS or HSD to access their prescribed medications at significantly reduced costs – with the added benefit of being paid $1.00 of XRPH tokens each time they use the card. The XRP Healthcare Prescription Savings Card offers savings of up to 80% off prescriptions and medications essential for managing EDS and HSD, including pain relievers, muscle relaxants, topical creams and patches, and gastrointestinal medications. With access to over 68,000 pharmacies in the USA, including Walmart, CVS Pharmacy, and Walgreens, individuals diagnosed with EDS or HSD can now enjoy substantial savings on their necessary treatments. "We are thrilled to support the EDS and HSD community through our sponsorship of this important charity event," said Kain Roomes, CEO and founder of XRP Healthcare. "At XRP Healthcare, we believe that everyone deserves access to affordable healthcare solutions. Our prescription savings card has the potential to save individuals with EDS or HSD hundreds of dollars annually, ensuring they can afford the medications they need to manage their condition effectively." As part of the sponsorship, the event will feature a special presentation by the Ehlers-Danlos Society, including an interview with Lara Bloom, President and CEO of the society in the next issue of the XRP Healthcare magazine – physical copies will be available for attendees at the event, as well as from chosen locations throughout Africa, America, United Kingdom and Europe. Professor Bloom has been a tireless advocate for individuals living with EDS and HSD, and her insights will provide invaluable support and inspiration to attendees. "I am deeply grateful to XRP Healthcare for their generous support of our charity event," said Lara Bloom. "Their dedication to improving access to affordable healthcare aligns perfectly with our mission to empower individuals living with EDS or HSD. Together, we can make a meaningful difference in the lives of those affected by this challenging condition." The Ehlers-Danlos Society event in Philadelphia promises to be a transformative gathering, uniting individuals, healthcare professionals, and advocates in the shared goal of raising awareness and support for EDS and HSD. Through initiatives like the XRP Healthcare prescription savings card, the EDS and HSD community can look forward to brighter and more accessible healthcare futures. About XRP Healthcare: XRP Healthcare is the first Pharma and Healthcare platform on the XRP Ledger, enabling fast global payments, improving healthcare access in emerging markets, and creating real-world utility by transforming global healthcare through mergers, acquisitions and blockchain. About the Ehlers-Danlos Society: The Ehlers-Danlos Society is a global community of patients, caregivers, healthcare professionals, and advocates dedicated to advancing research, education, and support for individuals living with Ehlers-Danlos syndrome (EDS) or hypermobility spectrum disorder (HSD) and related disorders and is based in New York, USA. Photo - Logo - SOURCE XRP Healthcare

This commitment is part of an ongoing series of major donations the Mike and Sofia Segal Foundation is making in support of rare disease research NEW YORK, Dec. 20, 2023 /PRNewswire/ -- The Ehlers-Danlos Society, the global non-profit dedicated to advancing and accelerating research in the Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD), today announced it has received a $6.7 million funding commitment from the Mike and Sofia Segal Foundation (the "Foundation") to advance its groundbreaking research initiatives. Continue Reading The Ehlers-Danlos Society Mike & Sofia Segal Foundation This transformative pledge—which includes several gifts by the Foundation—is aimed at shaping a future where individuals living with EDS and HSD can thrive. It will fuel innovative studies into the underlying mechanisms of EDS and HSD, identify novel therapeutic strategies, and enhance quality of life for individuals affected by these complex disorders. The Ehlers-Danlos syndromes are a group of inherited disorders impacting the body's connective tissues. Among the many complications of EDS, this leads to skin fragility, bruising, and poor healing; joint instability with subluxations, dislocations, injury and pain; other abnormalities of joint structure; abnormalities, of the eyes; dental issues; and, in some of the rarer types, life-threatening complications such as heart valve disease, rupture of organs (e.g., bowel), aneurysm formation, and rupture of major blood vessels. "This gift to EDS reflects our steadfast commitment to support cutting-edge treatments for, and educate the public about, a range of rare diseases," said Mike Segal. "A new milestone in our Foundation's work to support causes that have been overlooked and underfunded, this gift will help change the lives of those suffering from EDS and HSD. It is also just the beginning. We look forward to exploring similar initiatives focused on other rare diseases and neglected causes as we uphold our Foundation's mission to make the world a better place." Lara Bloom, President and CEO of The Ehlers-Danlos Society, emphasized the significance of the generous gifts: "This marks a turning point for both the Ehlers-Danlos Society and the EDS and HSD community. The support from the Mike and Sofia Segal Foundation is invaluable in propelling our research towards earlier diagnosis. The foundations we've laid since our inception in 2016 are now paving the way for substantial advancements and positive changes that lie ahead." In 1978, Mike and Sofia Segal arrived in the U.S. from present-day Ukraine with $120, a young child, and just two suitcases. In 1990, Mike launched LS Power from humble beginnings, growing it from a tiny start-up into a powerhouse in the energy sector, focused on power generation, electric transmission, and renewable energy infrastructure. Mike and Sofia created their family foundation to champion neglected causes. Today's funding commitment to EDS is part of a larger series of gifts the Foundation is making in support of rare disease research. In October 2023, the Foundation committed $17 million to the Leukemia & Lymphoma Society to help advance the treatment of chronic myelomonocytic leukemia (CMML), a rare type of blood cancer. And it intends to make additional gifts in the near future. The partnership between the Ehlers-Danlos Society and the Foundation marks a significant leap forward in the quest for breakthroughs in EDS and HSD research. It will leverage the expertise and dedication of the Ehlers-Danlos Society, a global leader in advocating for those affected by these complex conditions, and the Foundation's unwavering commitment to driving advancements in healthcare. The Ehlers-Danlos Society and the Foundation hope this investment will serve as a catalyst, inspiring related contributions and collaborations within the scientific community and beyond. About The Ehlers-Danlos Society: The Ehlers-Danlos Society is a global organization dedicated to advancing and accelerating research and education in Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD). The Ehlers-Danlos Society supports the development of effective and equitable EDS and HSD therapies and works collaboratively to improve the lives of individuals affected by EDS and HSD. In addition to funding groundbreaking research, The Ehlers-Danlos Society is the global organization providing life-changing support services, increasing access to care, and educating health professionals through its award-winning EDS ECHO program, a Project ECHO initiative, and global events program. To learn more about EDS and HSD and to get involved, please visit ehlers-danlos.com About The Mike and Sofia Segal Foundation: The Mike and Sofia Segal Foundation provides substantial capital and endowment grants to nonprofits with outstanding leadership that can demonstrate measurable, impactful outcomes in its areas of philanthropic interest. For media inquiries, interviews, or additional information, please contact: The Ehlers-Danlos Society Erin Simons, The Ehlers-Danlos Society [email protected] The Mike and Sofia Segal Foundation Jonathan Chavkin / Hallie Erlich, Prosek Partners [email protected] / [email protected] Dr. Misha Galperin, Zandafi Philanthropic Advisors [email protected] SOURCE The Ehlers-Danlos Society

-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 million as of Q2 2022- CARLSBAD, Calif., Aug. 4, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended June 30, 2022 and highlighted recent corporate progress. "It's been a very productive second quarter at TYRA, highlighted by the FDA clearance to proceed with our SURF301 study of TYRA-300. I couldn't be more pleased with the execution our team has demonstrated and we look forward to moving our first precision oncology therapy into the clinic," said Todd Harris, CEO of TYRA. "We also remain on track to submit an IND for TYRA-200 in the second half of 2022 and continue to advance our pipeline." Recent Corporate Highlights IND Clearance Received for TYRA-300. The U.S. Food and Drug Administration (FDA) cleared TYRA to proceed with its Phase 1/2 SURF301 clinical study of TYRA-300, an FGFR3-selective inhibitor, in patients with metastatic urothelial carcinoma of the bladder and urinary tract. SURF301 is a two-part study designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300. IND for TYRA-200 on Track. TYRA continued to advance TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma. TYRA remains on track to submit an IND with the FDA for TYRA-200 in the second half of 2022. Pipeline Progression. TYRA continued to progress its pipeline including programs targeting achondroplasia and other FGFR3-related skeletal dysplasias, FGFR4-related cancers, and REarranged during Transfection kinase (RET). Strengthened Leadership Team with Key Hires. During the second quarter of 2022, TYRA made key senior appointments to its leadership team of Sarah Honig as Vice President, Corporate Development and Strategy, and Ali Fawaz as General Counsel and Secretary. Second Quarter 2022 Financial Results Second quarter 2022 net loss was $15.1 million compared to $5.5 million for the same period in 2021. Second quarter 2022 research and development expenses were $12.0 million compared to $4.4 million for the same period in 2021. Second quarter 2022 general and administrative expenses were $3.4 million compared to $1.1 million for the same period in 2021. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million . About Tyra Biosciences Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Leveraging SNÅP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers. TYRA-300 is an FGFR3 selective inhibitor for oncology. TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3 related skeletal dysplasias, FGFR4-related cancers, and RET. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit and engage with us on LinkedIn. Forward-Looking Statements TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential to develop purpose-built therapies that improve clinical outcomes; and the expected IND submission timing for TYRA-200. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: we are early in our development efforts, have not tested any of our product candidates in clinical trials and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, and completion of preclinical studies and clinical trials; our dependence on third parties in connection with manufacturing, research and preclinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; unfavorable results from preclinical studies; results from preclinical studies or early clinical trials not necessarily being predictive of future results; our ability to maintain undisrupted business operations due to the COVID-19 pandemic, including delaying or disrupting our preclinical studies, manufacturing, and supply chain; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and proprietary technologies; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Amy Conrad [email protected] SOURCE Tyra Biosciences